Literature DB >> 25091576

The Axin2 rs2240308 polymorphism and susceptibility to lung cancer in a Chinese population.

Dan Liu1, Ling Li, Yuguang Yang, Wentao Liu, Jin Wu.   

Abstract

Axis inhibition protein 2 (Axin2) is a negative regulator of the canonical Wnt/β-catenin signaling pathway, and functions as a tumor suppressor in a number of human cancers. Previous pilot studies have suggested an association between Axin2 exon1 148 (rs2240308) SNP polymorphism and risk for lung cancer. In the present study, we aimed to investigate the Axin2 exon1 148 polymorphism and its association with lung cancer susceptibility in Han Chinese population. The Axin2 exon1 148 SNP was genotyped in 555 controls and 520 lung cancer patients using TaqMan SNP Genotyping Assays. Unconditional logistic regression analysis was used to calculate adjusted odds ratios (ORs) and 95% confidence intervals (CIs). We observed that the genotype frequencies of TC, TT, and CC were significantly different between controls and cases (χ(2) = 6.849, P = 0.03256, df = 2). Subjects carrying T allele (TC + TT genotypes) had decreased susceptibility to lung cancer as compared to those carrying CC genotype (OR = 0.733, 95% CI = 0.5726-0.9393, P = 0.01382). No significant association was found between rs2240308 polymorphism and histological subtypes of lung cancers. Findings from this study suggest that Axin2 exon1 T148C polymorphism (rs2240308) contributes to increased susceptibility to lung cancer in Chinese population. This further implicates Axin2 as a lung cancer-related gene.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25091576     DOI: 10.1007/s13277-014-2399-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  21 in total

1.  Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling.

Authors:  W Liu; X Dong; M Mai; R S Seelan; K Taniguchi; K K Krishnadath; K C Halling; J M Cunningham; L A Boardman; C Qian; E Christensen; S S Schmidt; P C Roche; D I Smith; S N Thibodeau
Journal:  Nat Genet       Date:  2000-10       Impact factor: 38.330

Review 2.  Wnt signaling in lung cancer.

Authors:  Julien Mazieres; Biao He; Liang You; Zhidong Xu; David M Jablons
Journal:  Cancer Lett       Date:  2005-05-10       Impact factor: 8.679

3.  Strong association between lung cancer and the AXIN2 polymorphism.

Authors:  Emine G Gunes; Ergun Pinarbasi; Hatice Pinarbasi; Yavuz Silig
Journal:  Mol Med Rep       Date:  2009 Nov-Dec       Impact factor: 2.952

4.  Regulation of axin2 expression at the levels of transcription, translation and protein stability in lung and colon cancer.

Authors:  Thomas A Hughes; Hugh J M Brady
Journal:  Cancer Lett       Date:  2006-02-28       Impact factor: 8.679

Review 5.  The links between axin and carcinogenesis.

Authors:  S Salahshor; J R Woodgett
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

Review 6.  Wnt/beta-catenin signaling.

Authors:  T Akiyama
Journal:  Cytokine Growth Factor Rev       Date:  2000-12       Impact factor: 7.638

7.  Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling.

Authors:  Janet Y Leung; Frank T Kolligs; Rong Wu; Yali Zhai; Rork Kuick; Samir Hanash; Kathleen R Cho; Eric R Fearon
Journal:  J Biol Chem       Date:  2002-04-08       Impact factor: 5.157

8.  Subcellular distribution of Wnt pathway proteins in normal and neoplastic colon.

Authors:  Christine B Anderson; Kristi L Neufeld; Raymond L White
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-18       Impact factor: 11.205

Review 9.  Wnt signaling in stem cells and lung cancer.

Authors:  B He; D M Jablons
Journal:  Ernst Schering Found Symp Proc       Date:  2006

Review 10.  Worldwide overview of the current status of lung cancer diagnosis and treatment.

Authors:  Paul A Bunn
Journal:  Arch Pathol Lab Med       Date:  2012-12       Impact factor: 5.534

View more
  10 in total

1.  Association of Wnt signaling pathway genetic variants in gallbladder cancer susceptibility and survival.

Authors:  Anu Yadav; Annapurna Gupta; Saurabh Yadav; Neeraj Rastogi; Sushma Agrawal; Ashok Kumar; Vijay Kumar; Sanjeev Misra; Balraj Mittal
Journal:  Tumour Biol       Date:  2015-12-29

2.  Genotypes and Haplotypes in the AXIN2 and TCF7L2 Genes are Associated With Susceptibility and With Clinicopathological Characteristics in Breast Cancer Patients.

Authors:  M A Rosales-Reynoso; V Rosas-Enríquez; A M Saucedo-Sariñana; M Pérez-Coria; M P Gallegos-Arreola; E Salas-González; P Barros-Núñez; C I Juárez-Vázquez; S E Flores-Martínez; J Sánchez-Corona
Journal:  Br J Biomed Sci       Date:  2022-01-25       Impact factor: 2.432

3.  -148 C/T polymorphism of Axin2 contributes to a decreased risk of cancer: evidence from a meta-analysis.

Authors:  AnYuan Zhong; Xue Pan; MinHua Shi; HuaJun Xu
Journal:  Onco Targets Ther       Date:  2015-07-29       Impact factor: 4.147

4.  Quantitative assessment of the association between AXIN2 rs2240308 polymorphism and cancer risk.

Authors:  Juan Gong; Yuan Jiang; Ningbo Hao; Bo Zhu; Yongsheng Li
Journal:  Sci Rep       Date:  2015-05-14       Impact factor: 4.379

5.  AXIN2 rs2240308 polymorphism contributes to increased cancer risk: evidence based on a meta-analysis.

Authors:  Zhitong Wu; Yifan Sun; Shifu Tang; Chunming Liu; Shengbo Zhu; Lili Wei; Hong Xu
Journal:  Cancer Cell Int       Date:  2015-07-04       Impact factor: 5.722

6.  New insights into the association between AXIN2 148 C/T, 1365 C/T, and rs4791171 A/G variants and cancer risk.

Authors:  Bin Xu; Wei Yuan; Li Shi; Li Zuo; Xing-Yu Wu; Wei Zhang; Qiaxian Wen
Journal:  Cancer Cell Int       Date:  2019-05-06       Impact factor: 5.722

7.  Variations in AXIN2 predict risk and prognosis of colorectal cancer.

Authors:  L Otero; E Lacunza; V Vasquez; V Arbelaez; F Cardier; F González
Journal:  BDJ Open       Date:  2019-10-16

8.  SOX7 co-regulates Wnt/β-catenin signaling with Axin-2: both expressed at low levels in breast cancer.

Authors:  Huidi Liu; Emilio Mastriani; Zi-Qiao Yan; Si-Yuan Yin; Zheng Zeng; Hong Wang; Qing-Hai Li; Hong-Yu Liu; Xiaoyu Wang; Hong-Xia Bao; Yu-Jie Zhou; Jun-Jie Kou; Dongsheng Li; Ting Li; Jianrui Liu; Yongfang Liu; Lin Yin; Li Qiu; Liling Gong; Shu-Lin Liu
Journal:  Sci Rep       Date:  2016-05-18       Impact factor: 4.379

9.  Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling.

Authors:  Yunli Tong; Yuting Liu; Hongming Zheng; Liang Zheng; Wenqin Liu; Jinjun Wu; Rilan Ou; Guiyu Zhang; Fangyuan Li; Ming Hu; Zhongqiu Liu; Linlin Lu
Journal:  Oncotarget       Date:  2016-05-24

Review 10.  Molecular regulation and pharmacological targeting of the β-catenin destruction complex.

Authors:  Eline C van Kappel; Madelon M Maurice
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.